Gydrelle (Estriol)

Gydrelle is used in clinical practice to address estrogen‑related changes of the lower genital tract.

• Relief of vaginal dryness associated with vulvovaginal atrophy.
• Reduction of itching, burning, or irritation in the vaginal area.
• Improvement of urinary symptoms linked to atrophic changes.
• Management of mild menopausal symptoms such as discomfort during intercourse.

Side effects reported with vaginal estriol products vary in frequency and severity.

Common

• Mild vaginal irritation or discharge.
• Slight spotting or spotting after intercourse.
• Temporary increase in vaginal discharge.

Serious

• Allergic reaction such as rash, swelling, or difficulty breathing.
• Unexplained vaginal bleeding.
• Signs of estrogen‑dependent tumor growth.

Before initiating Gydrelle, certain precautions should be considered to ensure safe use.

• Not recommended for women with known estrogen‑dependent cancers.
• Use caution if a history of blood clots or thromboembolic disorders exists.
• Avoid if active vaginal infection or unexplained vaginal bleeding is present.
• Discuss use with a healthcare provider during pregnancy or breastfeeding, as safety data are limited.
• Monitor for signs of hormonal imbalance, such as breast tenderness or mood changes.

Estriol can interact with other medications or substances that affect estrogen pathways or clotting mechanisms.

Avoid

• Combined use with systemic estrogen therapy or high‑dose hormonal contraceptives.
• Concurrent use of anticoagulants that increase bleeding risk.

Use with caution

• Medications that influence liver enzymes (e.g., CYP3A4 inhibitors).
• Hormone‑sensitive cancer treatments.
• Herbal supplements containing phytoestrogens.